Clinical Trial Update: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for UCART22 evaluating safety and early activity in relapsed or refractory CD22-positive B-cell acute lymphoblastic leukemia; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• UCART22

Snippet

Sponsor: Cellectis S.A. | Conditions: B-cell Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: RECRUITING